BFM
KPTI icon

Boothbay Fund Management’s Karyopharm Therapeutics KPTI Stock Holding History

Boothbay Fund Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.49M Buy
+268,300
New +$2.05M 0.02% 755
2020
Q2 		– Sell
-46
Closed -$1.32M – 1044
2020
Q1 		$1.32M Buy
46
+22
+92% +$6.07K 0.11% 233
2019
Q4 		$684K Hold
24
– – 0.06% 407
2019
Q3 		$343K Buy
+24
New +$3.25K 0.03% 543

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Boothbay Fund Management's KPTI Position: Q1 2026 in Review

Boothbay Fund Management increased its Karyopharm Therapeutics (KPTI) stake by 48% in Q1 2026, buying an estimated $527K and bringing the position to 213,810 shares worth $1.19M. The position accounts for 0.02% of the portfolio, ranked #860.

Boothbay Fund Management first reported a position in KPTI in Q2 2018 and has held it in 15 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Boothbay Fund Management held 213,810 shares of Karyopharm Therapeutics worth $1.19M as of Q1 2026.
  • Boothbay Fund Management bought 69,182 Karyopharm Therapeutics shares in Q1 2026, an estimated $527K.
  • Karyopharm Therapeutics made up 0.02% of Boothbay Fund Management's portfolio in Q1 2026, its #860 holding.
  • Boothbay Fund Management first reported a position in Karyopharm Therapeutics in Q2 2018 and has held it in 15 quarters since.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.